To register for the presentation, please follow this Zoom link: https://us02web.zoom.us/webinar/register/WN_Nx3kCIIOSmOj686nctwpRA. A replay will be available on the AVITA Medical website, ...

Feb. 13, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ ... to the same period in 2023 Gross profit margin of 85.8% "With the December approvals of RECELL GO mini and Cohealyx, we have ...

RECELL GO mini AVITA Medical receives FDA approval of RECELL GO mini, a new addition to the RECELL Spray-On Skin™ technology platform. VALENCIA, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical ...

Tech: Avita's Recell. Valencia-based Avita Medical Inc. has received FDA approval for a version of its second-generation Recell skin cell harvesting device designed to treat small-scale wounds.

Valencia-based Avita Medical Inc. has received FDA approval for a version of its second-generation Recell skin cell harvesting device designed to treat small-scale wounds. Avita’s original device, ...

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System ...

Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...

We've been getting creative with the best logo makers for branding your business online. It's difficult to understate the importance of good logo design - it's the quickest way for customers and ...

Save articles for future reference. Remplir is a collagen wrap used in nerve repair surgery and is intended to assist surgeons to improve outcomes in the repair and regeneration of damaged nerves. It ...

Previously full year 2024 revenue guidance was in the range of US$68-$70m. Avita is known for its Recell burns products, with the company announcing in December that the US Food and Drug ...

Additionally, AVITA is anticipating FDA approval for RECELL GO mini in December 2024, which could further expand its market reach. The company is also developing a comprehensive wound offering with ...